Regional anaesthesia and cancer metastases: the implication of local anaesthetics
- PMID: 24134442
- DOI: 10.1111/aas.12210
Regional anaesthesia and cancer metastases: the implication of local anaesthetics
Erratum in
- Acta Anaesthesiol Scand. 2014 Feb;58(2):262
Abstract
Clinical and basic science studies have demonstrated the anti-inflammatory properties of local anaesthetics. Recent studies have begun to unravel molecular pathways linking inflammation and cancer. Regional anaesthesia is associated in some retrospective clinical studies with reduced risk of metastasis and increased long-term survival. The potential beneficial effects of regional anaesthesia have been attributed mainly to the inhibition of the neuroendocrine stress response to surgery and to the reduction in the requirements of volatile anaesthetics and opioids. Because cancer is linked to inflammation and local anaesthetics have anti-inflammatory effects, these agents may participate in reducing the risk of metastasis, but their mechanism of action is unknown. We demonstrated in vitro that amide local anaesthetics attenuate tumour cell migration as well as signalling pathways enhancing tumour growth and metastasis. This has provided the first evidence of a molecular mechanism by which regional anaesthesia might inhibit or reduce cancer metastases.
© 2013 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Comment in
-
Important data about anaesthetics and cancer recurrence.Acta Anaesthesiol Scand. 2014 Mar;58(3):371-2. doi: 10.1111/aas.12250. Epub 2014 Jan 13. Acta Anaesthesiol Scand. 2014. PMID: 24417255 No abstract available.
-
In reply.Acta Anaesthesiol Scand. 2014 Mar;58(3):372. doi: 10.1111/aas.12260. Epub 2014 Jan 16. Acta Anaesthesiol Scand. 2014. PMID: 24433222 No abstract available.
Similar articles
-
Effect of perioperative lidocaine on metastasis after sevoflurane or ketamine-xylazine anaesthesia for breast tumour resection in a murine model.Br J Anaesth. 2018 Jul;121(1):76-85. doi: 10.1016/j.bja.2017.12.043. Epub 2018 Feb 22. Br J Anaesth. 2018. PMID: 29935598
-
Important data about anaesthetics and cancer recurrence.Acta Anaesthesiol Scand. 2014 Mar;58(3):371-2. doi: 10.1111/aas.12250. Epub 2014 Jan 13. Acta Anaesthesiol Scand. 2014. PMID: 24417255 No abstract available.
-
Regional anaesthesia and analgesia: relationship to cancer recurrence and survival.Br J Anaesth. 2015 Dec;115 Suppl 2:ii34-45. doi: 10.1093/bja/aev375. Br J Anaesth. 2015. PMID: 26658200 Review.
-
Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade.Anesthesiology. 2012 Sep;117(3):548-59. doi: 10.1097/ALN.0b013e3182661977. Anesthesiology. 2012. PMID: 22846676 Free PMC article.
-
Anaesthetic agents for advanced regional anaesthesia: a North American perspective.Drugs. 2005;65(6):745-59. doi: 10.2165/00003495-200565060-00003. Drugs. 2005. PMID: 15819588 Review.
Cited by
-
Single shot ultrasound-guided thoracic paravertebral block for opioid-free radical mastectomy: a prospective observational study.J Pain Res. 2019 Sep 11;12:2701-2708. doi: 10.2147/JPR.S211944. eCollection 2019. J Pain Res. 2019. PMID: 31571975 Free PMC article.
-
Systemic Anti-Inflammatory Effects of Intravenous Lidocaine in Surgical Patients: A Systematic Review and Meta-Analysis.J Clin Med. 2023 May 31;12(11):3772. doi: 10.3390/jcm12113772. J Clin Med. 2023. PMID: 37297968 Free PMC article. Review.
-
Impact of pediatric anesthesia management on cancer outcomes in children-a narrative review.Front Oncol. 2025 Jul 4;15:1621620. doi: 10.3389/fonc.2025.1621620. eCollection 2025. Front Oncol. 2025. PMID: 40687423 Free PMC article. Review.
-
Effect of lidocaine and ropivacaine on primary (SW480) and metastatic (SW620) colon cancer cell lines.Oncol Lett. 2019 Jul;18(1):395-401. doi: 10.3892/ol.2019.10332. Epub 2019 May 7. Oncol Lett. 2019. PMID: 31497075 Free PMC article.
-
Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial.Br J Anaesth. 2025 Mar;134(3):662-670. doi: 10.1016/j.bja.2024.10.015. Epub 2024 Nov 20. Br J Anaesth. 2025. PMID: 39572271 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources